

# Press Release

N°: 2006/3

---

from [Neurotune AG](#)

## **Neurotune announces second closing of Seed Financing Round**

**With the conclusion of its Second Seed Round Financing  
Neurotune adds another CHF 2.5 Mio to its funds.**

Schlieren, June 26<sup>th</sup> 2006. Neurotune AG today announced the second closing to its seed financing round. In addition to the funds invested in the first closing, CHF 2.5 Mio. in equity were raised in a second closing from Private Equity Invest AG, Zurich, through sale of shares from Neurotune's stock. The total capital raised in this round is CHF 7.39 Mio. The investment is meant to finance Neurotune's activities ahead, i.e. expand its chemistry program, the target validation and preclinical research.

"With Private Equity Invest we welcome an investor with a respectable track record in life sciences among our shareholders" Andreas J. Schulze, CEO of Neurotune says.

## About Neurotune AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.

## About Sarcopenia

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy –Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

The treatment of sarcopenia is a growing market with no available causal treatment.

\* \* \* \* \*

*This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes' business, investors should consult Neurotune.*

\* \* \* \* \*